Volume 4, Issue 3, May 2016, Page: 79-84
Diagnostic Value of Homocysteine, Cystatin C and Lipid Indices in Assessment of Cardiovascular Risk Status of Patients with Diabetes Type 2
Brown Holy, Dept. of Medical Laboratory Science, Rivers State University of Science and Technology, Npkolu, Port Harcourt, Nigeria
Joshua Marcella Tari, Dept. of Medical Laboratory Science, Rivers State University of Science and Technology, Npkolu, Port Harcourt, Nigeria
Received: Apr. 7, 2016;       Accepted: Apr. 19, 2016;       Published: May 3, 2016
DOI: 10.11648/j.ejpm.20160403.15      View  2738      Downloads  81
Abstract
Diabetes mellitus (DM) is characterized by hyperglycaemia and glycosuria due to defects in insulin secretion from the Islets of Langerhans and associated with cardiovascular disease (CVD). The imperativeness to assess effectiveness of various cardiovascular risk tools is critical with increasing rate of people with diabetes type 2. Study was aimed at the assessment and evaluation of the diagnostic relevance of homocysteine, Cystatin C, cardiovascular risk indices in the risk profile of cardiovascular diseases in Type 2 diabetes mellitus patients. A total of 165 patients were involved in the study, of which 100 were diabetic (test) and 65 non-diabetics (control). The diabetic subjects were those whose glycated haemoglobin (HbA1C) levels were ≥ 6.5%. HbA1C was estimated quantitatively by immunochemical method, Homocysteine (Hcy), Cystatin C, Lipoprotein (a) (Lp (a) were measured by Enzyme Linked Immunosorbent assay (ELISA) method; Glucose oxidase method was used for the determination of fasting plasma glucose (FBS). The results showed elevated serum homocysteine (Hcy), Lp (a) among the diabetics as compared to the non-diabetic subjects (p<0.05). The diabetic subjects also depicted higher Cystatin C (Cys C) levels, in the diabetic type 2 patients compared to the non-diabetic patients. The lipid profile levels in the diabetic subjects showed higher mean values of total cholesterol and triglycerides, (p < 0.05) as compared with the non-diabetic. The percentage risk predictive values of cardiovascular disease in the diabetic sub-population with these risk indices showed Hcy with a sensitivity of 96%, specificity of 96.9% and an accuracy of 96.5% as compared to Cys C with a sensitivity of 95%, specificity of 96.9%, accuracy of 95.9% also compared with that of Lp (a) with a sensitivity of 91%, specificity of 100% and an accuracy of 95.5%. The level of accuracy of Hcy, Cys C and then Lp (a) amongst other indices showed that these diagnostic tools could provide better platform in cardiovascular risk profiling of T2DM patients and should be encouraged.
Keywords
Diabetes, Cardiovascular, Risk, Cystatin C, Homocysteine, Lipids
To cite this article
Brown Holy, Joshua Marcella Tari, Diagnostic Value of Homocysteine, Cystatin C and Lipid Indices in Assessment of Cardiovascular Risk Status of Patients with Diabetes Type 2, European Journal of Preventive Medicine. Vol. 4, No. 3, 2016, pp. 79-84. doi: 10.11648/j.ejpm.20160403.15
Copyright
Copyright © 2016 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Katarzyna, K., Artur, C., Ewa, C., and Anna, J., (2015). Homocysteine – relation to hypertension, age and smoking in patients with newly diagnosed essential hypertension. Journal of Medical Science, 2 (82), 90-95.
[2]
Wang, X., Qun, X., Dermritas, H., Li, T. Mao, G. Huo, Y. Sun, N. & Liu, L. (2007). Efficacy of folic and supplements in stroke prevention, a meta analysis. Lancet, 369, 1876–1882
[3]
McCully, K. S. (2011). Vascular pathology of homocysteine implications for the pathogenesis of atherosclerosis, American Journal of Pathology, 56, 111-128
[4]
Den H. M., Rosendaal F. R., Blom H. J., Gerrrits W. B, Bos, G. M (1998). Hyperhomocysteine and venous thrombosis, a meta-analysis. Journal of Thrombosis and Haemostasis 80, 874-877
[5]
Ward M., McNulty H., Pentieva K., McPartlin J., Strain J. J., Weir D. G. & Scott J. M.(2000). Fluctuations in dietary methionine intake do not alter plasma homocysteine concentration in healthy men, Journal of Nutrition, 130 (11), 2653-2657
[6]
Clarke, R., Peden, J. F, Hopewell, J. C. (2013). PROCADIS consortium, Genetic variants associated with Lp (a) Lipoprotein a, levels and coronary disease. Journal of New England of Medicine, 361 (26), 2518-2528
[7]
Wild, S., Roglic, G., Green, A., Sicee, R. & King, H. (2004). Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Journal of Diabetic Care,. 27,1047–1053
[8]
Gregg E. W., Cheng Y. J., Cadwell B. L., Imperatore G, William D. E., Flegal, K. M., Narayan & K. M., Williamson, D. F (2005). Secular trends in cardiovascular disease risk factors according to body mass index in US adults. Journal of American Medical Association, 293, 1868-1874
[9]
Yun K. J., Mi R. K., Jung E. H., Ji Y. M., Sang H. S., Sang S. K., Bo H. K., Soo H. L., Yong K. K. & In J. K. (2011). Cystatin C as an Early Biomarker of Nephropathy in Patients with Type 2 Diabetes, Endocrinology, Nutrition & Metabolism, Journal of Korean Medical Science, 26, 258-263
[10]
Pucci, L., Triscornia, S., Lucchesi, D. (2007). Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Journal of Clinical Chemistry, 53, 480-488
[11]
National Kidney Foundation (2002). Clinical practice guideline to define chronic kidney disease evaluation, classification and stratification. American Journal of kidney
[12]
American Diabetes Association (2003). Management of dyslipidemia in adults with diabetes mellitus type 2 (position statement). Journal of Diabetes Care, S83-S86
[13]
Dhia, R. B, Hellara, I., Harzallah, O., (2012): Evaluation of the renal function in type 2 diabetes, clearance calculation or cystatin c. Analyses de Biologic Clinique 70, (3), 287-294
[14]
Hojs, R., Bevc, R., Ekart, M., Gorenjak, Puklaverc, L. (2008). Serum cystatin C – based equation compared to serum creatinine-based equations for estimation of glomerular filtration rate in patients with chronic kidney disease. Journal of Clinical Nephrology, 70, 10-17
[15]
Clark, R., Halsey, J., Lewington, S., Lonn, E., Armitage, J., Manson, J. E., Bonna, K. H., Spence, J. D., (2012). Effect of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer and cause specific mortality, and meta-analysis of 8 randomized trials involving 37, 485 individuals. Arch International Medicine 170, 1672-1631
[16]
Wang, S. R., Ynz, H. C., Messias, A. C. & Floegel, A. H., (2012). Novel biomarkers for pre-diabetics identified by metabolomics. Molecular System Biology,. 8, 615
[17]
Mazza A, Bossone E, Mazza F, Distante A. (2005). Reduced serum homocysteine levels in type 2 diabetes. Nutr Metabolism Cardiovasc Dis; 15: 118–24
[18]
Ebesunun, M. O., & Obajobi, E. O. (2012). Elevated plasma homocysteine in type 2 diabetes mellitus: a risk factor for cardiovascular diseases. The Pan African Medical Journal, 12, 48.
[19]
Bostom A., Brosnan J. T, Hall, B, Nadeau M. R and Selhub, J. (1995): Net uptake of plasma homocysteine by the rat kidney in vivo, Atherosclerosis, 116, 59-62
[20]
Alaaeldin, M. B., Ayman, A. S. F., Nada, A., Puja, M. T., Elamin, A., & Fauzia, R. (2015). Cystatin C and Its Role in Patients with Type 1 and Type 2 Diabetes Mellitus, Advances in Endocrinology, 1-6
[21]
Robinson, K., Clark R., Naughton, E., Cahalane, S., (1995): Hyperhomocysteinemia an independent risk factor for vascular disease. New England Journal of Medicine 324, 1149-1155
[22]
Shai, I., Jiang, R., Manson J. E, Stampfer, M. J., Willett, W. C., Colditz, G. A, Hu, F. B (2004): Ethnicity, Obesity, and Risk of Type 2 Diabetes in Women, A 20-year follow-up study, Circulation, 2824-2830
[23]
Dudman, N. P. B (1999): An alternative view of homocysteine, Lancet, 354, 2072-2074
[24]
Randers, E., Erlandsen, EJ, (1999): Serum cystatin C as an endogenous marker of the renal function: a review, Clinical Chemistry and Laboratory Medicine 7, 389–395
[25]
Norlund L., Grubb A., Fex G., Lksell H., Nilsson J. E., Schenck H., Hultberg B. (1998). The increase of plasma homocysteine with age is partly due to the deterioration of renal function as determined by plasma cystatin C. Clinical chemistry and Laboratory Medicine, 36, 175–178
[26]
Yeolekar, M. E. (2010). Coronary artery disease in Asian Indians, Journal of Post Graduate Medicine 44, 26
Browse journals by subject